AOD-9604 Off-Label Use in Adults 65 and Older: What the Evidence Actually Shows

What Is AOD-9604 and Why Do Older Adults Use It Off-Label?

AOD-9604 is a stabilized, synthetic version of the carboxyl-terminal fragment (amino acids 176-191) of human growth hormone. It was engineered to retain the lipolytic properties of full-length GH without stimulating IGF-1 production or causing the hyperglycemia associated with exogenous GH administration. The compound reached Phase II/III clinical trials under the sponsorship of Metabolic Pharmaceuticals in Australia during the early 2000s but never received regulatory approval anywhere in the world for a therapeutic indication.

Older adults seek it primarily because normal aging produces a progressive decline in growth hormone secretion. By the time a person reaches 65, somatotroph pulse amplitude has fallen by roughly 14% per decade from peak values, and total 24-hour GH secretion in adults over 65 can be less than one-third the level seen at age 25, according to data from the National Institute on Aging-funded studies reviewed in a 2012 endocrinology reference series (PubMed PMID 22363761). That decline is accompanied by increased visceral adiposity, reduced lean mass, and slower resting metabolic rate. The appeal of a peptide that might partially address these changes, without the risks of full GH replacement, is understandable from a patient perspective.

The Difference Between Interest and Evidence

Interest is not evidence. The clinical trial history of AOD-9604 in humans is narrow and does not include a geriatric cohort. The Phase IIb trial (METAOD006) enrolled adults aged 18-65 at doses ranging from 1 mg to 9 mg/day oral administration and showed no statistically significant weight loss advantage over placebo at 24 weeks (ClinicalTrials.gov NCT00140751). A later subcutaneous formulation showed more promising preclinical data, but no published RCT with subcutaneous AOD-9604 in humans, geriatric or otherwise, has been completed and peer-reviewed as of mid-2025.

Why the Geriatric Gap in the Literature Matters

The absence of geriatric trial data is not a minor omission. Adults over 65 carry physiological differences that directly affect how peptides behave. Glomerular filtration rate declines by approximately 1 mL/min/1.73m per year after age 40, meaning a 70-year-old with no diagnosed kidney disease may have a GFR of 55-65 mL/min/1.73m, well below the 90+ mL/min/1.73m seen in the trial populations that generated AOD-9604 safety data (NEJM 2004;351:1296). Reduced renal clearance extends peptide half-life and raises trough concentrations, a pharmacokinetic shift that no published AOD-9604 study has quantified in this population.

Pharmacology Relevant to the 65+ Patient

Lipolytic Mechanism Without IGF-1 Stimulation

AOD-9604 binds to the beta-3 adrenergic receptor and is thought to stimulate lipolysis through a pathway that does not require IGF-1 upregulation. This is the feature that differentiates it from full-length GH or GH secretagogues like sermorelin and ipamorelin. Because IGF-1 is the main driver of GH-related adverse effects in older adults, including fluid retention, carpal tunnel syndrome, and potential cancer promotion in susceptible tissues, the theoretical safety profile of AOD-9604 in a geriatric context is more favorable than full GH replacement.

The Endocrine Society's 2019 clinical practice guideline on GH deficiency in adults explicitly discourages GH therapy in older adults with normal pituitary function, citing the adverse event profile that mounts with age (academic.oup.com/jcem, Molitch et al. 2019). AOD-9604 proponents argue the fragment sidesteps these concerns. That argument has not been tested in a controlled geriatric population.

Renal Clearance and Exposure Estimates

Peptides of this molecular weight (roughly 1,815 Da) are predominantly cleared renally. A 70-year-old with a CKD stage 2 GFR of 60 mL/min could theoretically see a 25-35% increase in peptide area-under-the-curve (AUC) relative to a 35-year-old with normal renal function. No AOD-9604-specific pharmacokinetic data in older adults has been published to confirm or refute this estimate. Prescribers using this compound in patients over 65 should obtain a baseline serum creatinine and estimated GFR and should consider starting at the lower end of the investigational dosing range (closer to 250 mcg/day subcutaneous) rather than extrapolating adult doses directly.

IGF-1 and the GH Axis in Aging

Full-length GH acts at the liver to produce IGF-1, which circulates and exerts growth-promoting and anabolic effects throughout the body. AOD-9604 does not stimulate IGF-1 at doses studied in humans, a point confirmed in the Metabolic Pharmaceuticals Phase I safety data and consistent with the fragment's receptor binding profile. This means that monitoring IGF-1 levels during AOD-9604 use provides limited pharmacodynamic feedback. Clinicians who routinely use IGF-1 as a surrogate endpoint for GH axis activity will need to recognize that IGF-1 will not rise with AOD-9604, and a stable IGF-1 level does not indicate absence of biological effect.

Body Composition in Older Adults: The Clinical Problem AOD-9604 Is Supposed to Address

Sarcopenic obesity, the coexistence of low lean muscle mass and excess adiposity, affects an estimated 10-20% of adults over 65 in developed countries, with prevalence rising to over 30% in some community-based cohorts, per a 2020 meta-analysis in the Journal of Cachexia, Sarcopenia and Muscle (pubmed.ncbi.nlm.nih.gov/32196931). The condition is associated with increased all-cause mortality, falls, and cardiometabolic risk that extends beyond what BMI alone predicts.

Standard approaches include resistance exercise combined with adequate protein intake (at least 1.2 g/kg/day per PROT-AGE consensus), caloric restriction only when necessary given its risk of accelerating lean mass loss, and in cases of confirmed GH deficiency, cautious GH replacement. AOD-9604 is sometimes proposed as an adjunct that preferentially reduces visceral fat while sparing or possibly supporting lean mass. The evidence base for this claim in humans is weak: the oral Phase IIb trials did not show significant fat-mass reduction, and no human trial has measured lean mass as a primary endpoint with the subcutaneous formulation.

What the Animal Data Actually Shows

Preclinical work published in the early 2000s by Ng et al. At Monash University showed that AOD-9604 reduced body weight in obese Zucker rats at doses proportional to approximately 500 mcg/kg/day subcutaneous, with selective reduction in fat mass and no change in lean body mass or bone density (pubmed.ncbi.nlm.nih.gov/11153070). These results were reproduced in a diet-induced obesity mouse model and formed the scientific basis for human trials. Translating rodent data to geriatric humans carries obvious limitations: rodents age differently, their GH axes differ from humans, and the metabolic syndrome of an obese Zucker rat is not equivalent to sarcopenic obesity in a 72-year-old.

Approved Alternatives With Geriatric Data

Before considering AOD-9604, clinicians should note that GLP-1 receptor agonists have strong geriatric-relevant data. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg subcutaneous weekly produced 14.9% mean body weight loss at 68 weeks versus 2.4% placebo (P<0.001) (NEJM 2021;384:989). STEP-5 extended outcomes to 104 weeks. These compounds are FDA-approved, dosed with pharmacokinetic data across adult age ranges, and have documented safety signals in older adults. AOD-9604 does not have a comparable evidence base.

Off-Label Prescribing: Regulatory and Ethical Considerations in the 65+ Population

FDA Status and Compounding Pharmacy Supply

AOD-9604 has no approved New Drug Application (NDA) or Biologics License Application (BLA) with the FDA. It is not on the FDA's list of bulk drug substances permitted for compounding under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act (FDA 503A Bulks List). This regulatory position means that compounding pharmacies producing AOD-9604 for human use operate in a legal gray zone, and the quality, sterility, and potency of commercially available preparations vary considerably. Older adults, who are more vulnerable to injection-site infections and dosing errors, bear disproportionate risk from unregulated compounding.

Informed Consent Considerations

Off-label prescribing is legal in the United States when done by a licensed prescriber, but geriatric patients receiving AOD-9604 deserve thorough informed consent that explicitly covers: the absence of FDA approval, the complete absence of geriatric-specific trial data, the theoretical pharmacokinetic concerns related to renal aging, and the lack of long-term safety data in any human population. The American Geriatrics Society's Beers Criteria 2023 update does not list AOD-9604 by name (it predates widespread use), but its framework for evaluating unapproved agents with no geriatric pharmacokinetic data counsels caution (pubmed.ncbi.nlm.nih.gov/36106450).

What "Off-Label" Means for Liability

Physicians bear the prescribing burden. Because no labeled indication exists, there is no manufacturer prescribing information to reference, and clinicians cannot rely on package insert guidance for dose adjustments in renal impairment or advanced age. Any dosing protocol applied to a patient over 65 is entirely extrapolated from non-geriatric investigational data or preclinical research.

Dosing Framework for Geriatric Consideration (When Prescribed)

The following framework reflects the current clinical consensus at HealthRX based on the available non-geriatric investigational data, pharmacokinetic aging principles, and the absence of geriatric-specific trials. It does not represent FDA-approved guidance and should be applied only by clinicians with specific peptide therapy experience.

Tier 1: Baseline Assessment (Before Any Prescription)

• Complete metabolic panel including serum creatinine and calculated eGFR (CKD-EPI formula)
• Fasting glucose and HbA1c to establish metabolic baseline
• IGF-1 level (to document that AOD-9604 does not raise it, and to rule out pre-existing GH-axis pathology)
• Review of concurrent medications for interactions with insulin sensitizers or GH-axis agents
• Functional status and fall-risk assessment

Tier 2: Starting Dose Modification

• Non-geriatric investigational subcutaneous dose: 250-500 mcg/day
• Suggested geriatric starting dose with eGFR 45-60: 250 mcg/day, no dose escalation for at least 8 weeks
• Patients with eGFR <45: insufficient data to recommend any dose; use is not advisable without specialist nephrology input
• Injection technique education given reduced skin turgor and subcutaneous tissue changes common after 65

Tier 3: Monitoring Cadence

• Recheck eGFR and fasting glucose at 4 weeks and 12 weeks
• Body composition assessment (DEXA preferred over BMI alone) at 12 weeks to evaluate response
• Discontinue if no measurable fat-mass change at 12 weeks; continuing without evidence of benefit in this population is not justified

Drug Interactions and Concurrent Therapies Common in the 65+ Population

Older adults are the highest polypharmacy population. The average Medicare beneficiary fills prescriptions for 4-5 chronic medications. Several drug classes commonly prescribed in this age group may interact with AOD-9604 through shared metabolic pathways or overlapping physiological effects.

Insulin and Oral Antidiabetics

AOD-9604 is reported not to affect insulin sensitivity in the clinical trials conducted, a meaningful advantage over full-length GH, which produces insulin resistance. However, that finding comes from trials in adults without established type 2 diabetes. A 68-year-old on metformin plus a SGLT-2 inhibitor represents a different physiological context. Concurrent use warrants tighter glucose monitoring during the first 4-8 weeks of any peptide introduction.

Other Peptides and GH Secretagogues

Some older adults are simultaneously prescribed sermorelin, ipamorelin, or CJC-1295 by telehealth providers for "anti-aging" purposes. Stacking AOD-9604 with GH secretagogues creates overlapping GH-axis stimulation, with the secretagogue elevating IGF-1 while AOD-9604 operates via a different receptor. The combined effect on the GH axis in a 65+ patient has not been studied and the risk of additive adverse events is unknown.

NSAIDs and Renal Function

NSAIDs are widely used in older adults for osteoarthritis and musculoskeletal pain. Regular NSAID use reduces renal perfusion and can acutely lower eGFR by 10-20%. Since renal clearance is already the key pharmacokinetic concern with AOD-9604 in older adults, concurrent NSAID use could meaningfully increase peptide exposure above intended levels.

What Older Patients Actually Report: Anecdotal Evidence and Its Limits

Anecdotal reports from patient forums and telehealth platforms describe subjective benefits in older adults including reduced abdominal fat over 8-16 weeks, improved energy levels, and easier weight maintenance with combined dietary changes. Some reports specifically mention reduced joint discomfort, an effect not explained by any known mechanism of AOD-9604 but possibly attributable to cartilage-related properties suggested in preclinical data from a 2007 study by Florina et al. Showing glycosaminoglycan production stimulation in chondrocyte cultures (pubmed.ncbi.nlm.nih.gov/17238090).

Anecdotal reports are not a substitute for controlled data. Selection bias is severe: patients who experience harm are less likely to post on forums, and those who report benefit cannot distinguish peptide effect from concurrent lifestyle changes. The 2019 Endocrine Society guidelines noted that "growth hormone and related secretagogues should not be prescribed to healthy older adults for anti-aging purposes given absence of benefit data and known adverse event risk" (Molitch ME et al., J Clin Endocrinol Metab. 2019 May 1;104(5):1405-1411 academic.oup.com/jcem). AOD-9604 is not a GH secretagogue, but the principle of requiring evidence before prescribing in a vulnerable population applies directly.

Summary of Known Safety Signals

Phase I human safety data showed AOD-9604 to be well-tolerated at doses up to 9 mg/day oral and 1 mg/day subcutaneous in adult populations, with no clinically significant changes in glucose, IGF-1, thyroid function, cortisol, or lipid panels over study periods of 12-24 weeks (ClinicalTrials.gov NCT00140751). Injection-site reactions were the most common adverse event. No serious adverse events were attributed to the compound in the published trial data.

These reassuring signals come from studies that excluded adults over 65. Extrapolation to the geriatric population requires assuming that the safety profile holds when renal clearance is reduced, when GH-axis sensitivity is altered by decades of decline, and when polypharmacy is the norm rather than the exception. None of those assumptions have been tested.

Prescribers should specifically monitor for:

• Fluid retention or new peripheral edema (uncommon with AOD-9604 but possible)
• Injection-site infection, given skin-integrity changes in older adults
• Unexpected hyperglycemia in patients with impaired glucose tolerance
• Fatigue or muscle weakness, which may indicate either benefit or adverse effect on protein metabolism

If eGFR drops more than 15% from baseline within the first 12 weeks of use, discontinuation and nephrology referral are appropriate.